Infectious diseases caused by drug-resistant bacteria are one of the most serious problems currently facing the medical field, as warned by the CDC 1 and the WHO. 2, 3 Among these drug-resistant bacteria, methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis/faecium (VRE) are two of the most intractable nosocomial pathogens that show broad-range drug resistance. Vancomycin has been used as the last resort for the treatment of infectious diseases caused by S. aureus and enterococci; however, since 1986, VRE strains have emerged and become widespread. 4, 5 Since the beginning of this century, vancomycin intermediate-resistant S. aureus have been frequently isolated 6 and 33 strains of vancomycin high-level resistant S. aureus have also emerged in Asian countries and in the United States. 7 Effective drugs against these pathogens are urgently needed.
During the course of our screening for antibiotics active against both methicillin-resistant S. aureus and VRE, pargamicin A (PRG-A, Figure 1 ) was discovered from the fermentation broth of soil actinomycete strain Amycolatopsis sp. ML1-hF4. 8 PRG-A is a structurally unique cyclic peptide consisting of N-methyl-3-hydroxy valine, 4-hydroxy piperazic acid (4-OH-Pip), sarcosine, phenylalanine, N-hydroxy isoleucine (NOH-Ile) and piperazic acid (Pip), which shows excellent in vitro antibacterial activity that is either comparable to, or more potent than, that of other currently available drugs, including vancomycin. 8 Our previous studies revealed that PRG-A exerted rapid bactericidal activity against staphylococci and enterococci via a mechanism that involved disruption of the membrane integrity of the target cells, 9 a mode of action distinct from that of daptomycin. 9, 10 During the process of optimization of PRG-A production, we discovered new active components PRG-B, -C and -D (Figure 1 ) in the culture broth of the PRG-A-producing strain Amycolatopsis sp. ML1-hF4. This present study investigates the fermentation, isolation, structural elucidation and antimicrobial activities of these new PRG-A-analogs and discusses the structure-activity relationship of PRGs.
The PRG-A producing strain was cultured for 3 days at 30°C in liquid media consisting of 2% galactose, 2% dextrin hydrate, 1% soytone, 0.5% corn steep liquor, 0.2% ammonium sulfate and 1.0% calcium carbonate (pH 7.0 before sterilization). This seed culture was inoculated (3%) into media consisting of 0.33% galactose, 0.33% dextrin hydrate, 0.17% glycerol, 0.17% soytone, 0.083% corn steep liquor, 0.033% ammonium sulfate and 0.2% calcium carbonate (pH 7.0 before sterilization), and cultivated for 7 days at 27°C with shaking (180 r.p.m.). This media was sixfold diluted compared with that reported at the time of PRG-A discovery. 8 The resulting 2.5 l culture broth was then centrifuged (3000 g, 10°C, 15 min) and the supernatant was applied to a Diaion HP-20 column (Mitsubishi Chemical Co., Tokyo, Japan, 300 ml wet volume). The column was washed with 1 liter each of distilled water, 40% aqueous methanol and was eluted with 90% aqueous methanol. The eluted fraction was dried Table S1 ). The molecular formulae of PRG-A, B, C and D were C 34 Supplementary  Figures S10-S12 ). NMR data are summarized in Table 1 . The molecular formulae, IR spectra, optical rotations and NMR spectral data of the PRGs indicated that they are closely related in structure, except for the Pip or NOH-Ile moieties. The structures of PRG-B, C and D were determined by comparison with the NMR data for PRG-A and the structural differences are shown in Figure 2 .
The molecular formula of PRG-B was C 33 H 50 N 8 O 9 , which was smaller by one CH 2 unit than PRG-A. The antimicrobial activities of the PRGs are summarized together with that of vancomycin in Table 2 . MICs were determined as previously reported. 13 PRG-A and PRG-C exhibited potent antibacterial activity against Gram-positive bacteria including methicillinresistant S. aureus and VRE; the antibacterial activity of PRG-B and PRG-D against these bacteria was weaker. PRG-C and PRG-D, which possess a polar group in the northern region of Pip, exhibited four-to eightfold weaker antibacterial activity against staphylococci than against enterococci, whereas PRG-A and PRG-B showed equal activity against staphylococci and enterococci. This suggested that the presence of polar groups in the northern region of Pip might be disadvantage to the interaction with staphylococcal membrane. VRE were as sensitive to all of the PRGs as vancomycin-sensitive enterococci and all of the tested compounds, including vancomycin, showed no activity against Gram-negative bacteria.
The only structural differences between the PRGs are in the Pip-(NOH-Ile) moiety of PRG-A. However, despite this structural similarity, the antimicrobial activities of the PRGs showed remarkable differences. This suggested that the side chain of isoleucine residues and the northern Pip structures might have an important role in the interaction with the bacterial membrane and the localization of PRGs on the bacterial surface. Further studies into Pip containing cyclic peptides, such as the PRGs, may therefore result in the discovery of new types of antibacterial drugs that selectively disturb the bacterial membrane. 
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